	Symptomatic disease: any	Severe disease: any	Symptomatic disease:D614G		Infection: D614G		Asymptomatic: any	Asymptomatic: B.1.1.7	Severe disease: D614G		Infection: B.1.1.7	Symptomatic disease: B.1.1.7	Severe disease: B.1.1.7	Infection: B.1.351	Symptomatic disease: B.1.351	Severe disease: B.1.351	Symptomatic disease: P.1	Severe disease: P.1		
Vaccine	**Complete regimen**	**Complete regimen**	**1st dose**	**Complete regimen**	**1st dose**	**Complete regimen**	**Complete regimen**	**Complete regimen**	**1st dose**	**Complete regimen**	**Complete regimen**	**Complete regimen**	**Complete regimen**	**Complete regimen**	**Complete regimen**	**Complete regimen**	**Complete regimen**	**Complete regimen**	**Notes**	**Source**
Pfizer-BioNTech		Israel national: 97.5% (97.1% to 97·8%)	Trial (Day 0-21): 52% (29.5% to 68.4%) Israel SHEBA (Day 15-28): 85% (71% to 92%) Israel CLALIT (Day 14-20): 57% (50% to 63%) Israel Maccabi (Day 13-24): 51.4% (-7.2% to 78.0%) England (Day 28+, 80+ yrs): 57% (48% to 63%)	Trial (original): 94.6% (90.3% to 97.6%) Trial (updated): 91.3% (89.0% to 93.2%) Israel CLALIT: 94% (87 to 98%)[j] England (80+ yrs): 88% (84% to 90%)	UK SIREN (Day 21+): 72% (58% to 86%) Israel SHEBA (Day 15-28): 75% (72% to 84%) Israel CLALIT (Day 14-20): 46% (40% to 51%)	UK SIREN: 86% (76% to 97%) Israel CLALIT: 92% (88 to 95%)		Israel National: 91.5% (90.7% to 92·2%)	Trial: 100% (-52% to 100%) Israel CLALIT (Day 14-21): 62% (39% to 80%)	Trial: 75% (-152.6% to 99.5%) Israel CLALIT: 92% (75% to 100%)	Qatar: 89.5% (85.9% to 92.3%)	Israel national: 97.0% (96.7% to 97·2%)	Qatar: 100.0% (81.7% to 100.0%)	Qatar: 75% (70.5% to 78.9%)	Trial (SA): 100% (53.5% to 100.0%)	Qatar: 100.0 (73.7–100.0)			Trial, Israel and UK studies assumed to apply to ancestral/D614G/B.1.1.7 outcomes	www.nejm.org/doi/full/10.1056/NEJMoa2034577 www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00448-7/fulltext www.nejm.org/doi/full/10.1056/NEJMoa2101765 papers.ssrn.com/sol3/papers.cfm?abstract_id=3790399 www.medrxiv.org/content/10.1101/2021.01.27.21250612v1 assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/963532/COVID-19_vaccine_effectiveness_surveillance_report_February_2021_FINAL.pdf https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-confirm-high-efficacy-and-no-serious https://www.nejm.org/doi/full/10.1056/NEJMc2104974 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00947-8/fulltext
Moderna				Trial: 94.1% (89.3% to 96.8%)	Trial (Day 0-21): 89.6% (85.2% to 92.6%)					Trial: 100% (NE)									Trial assumed to apply to ancestral/D614G/B.1.1.7 outcomes	www.nejm.org/doi/full/10.1056/NEJMoa2035389
Oxford-AstraZeneca	Trial (UK, SA, Brazil): 66.7% (57.4% to 74.0%)			Trial (UK): 74.2% (65% to 81%)		Trial (UK): 51.9% (42.0% to 60.1%)						Trial (variant-specific): 74.6% (41.6% to 88.9%)			Trial (variant-specific): 10.4% (-76.8 to 54.8%)		Trial (Brazil SD, non-variant-specific): 57.6% (40.7% to 69.7%)		Variant efficacy based sequenced samples for B.1.1.7 and B.1.351 and trial location for P.1. (Brazil)	www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32661-1/fulltext www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00432-3/fulltext papers.ssrn.com/sol3/papers.cfm?abstract_id=3779160 www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-AZD1222-background-2021.1
Johnson & Johnson	Trial (USA, SA, Brazil): 66.1% (55.0% to 74.8%)			Trial (USA): 72.0% (58.2% to 81.7%)			Trial (USA, SA, Brazil): 65.5% (39.9% to 81.1%)			Trial (USA): 85.9% (-9.4% to 99.7%)					Trial (SA): 64.0% (41.2% to 78.7%)	Trial (SA): 81.7% (46.2% to 95.4%)	Trial (Brazil): 68.1% (48.8% to 80.7%)	Trial (Brazil): 87.6% (7.8% to 99.7%)	Efficacy is based on 28+ day outcomes Variant efficacy based on trial location (USA, Brazil, South Africa): 94.5% of sequenced samples in South Africa were B.1.351 69.4% of sequenced samples in Brazil were P.1 96.4% of sequenced samples in USA were D614G	www.fda.gov/media/146218/download www.fda.gov/media/146217/download www.fda.gov/media/146219/download
Novavax				Trial (UK): 89.3% (75.2% to 95.4%)								Trial (variant-specific): 86% (59.2% to 95.0%)			Trial (SA): 51.0% (-0.6% to 76.2%)				92.7% of sequenced samples in South Africa were B.1.351	ir.novavax.com/static-files/2f6f14cb-3205-4719-b28c-1711793b9782 https://www.nejm.org/doi/full/10.1056/NEJMoa2103055
Sputnik V				Trial: 91.6% (85.6% to 95.2%)						Trial: 100% (94.4% to 100%)									Trial assumed to apply to ancestral/D614G/B.1.1.7 outcomes	www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00234-8/fulltext
CoronaVac				Trial (Indonesia): 65.3% (25 cases) Trial (Turkey): 91.3% (29 cases)													Trial (Brazil): 50.3% (252 cases: 167 placebo, 85		Unpublished reports	www.nature.com/articles/d41586-021-00094-z
Sinopharm	Trial: 72.5% (not reported)																		Unpublished reports	www.scmp.com/news/china/science/article/3122980/covid-19-vaccines-made-chinas-sinopharm-cansino-release-efficacy
CanSinoBio	Trial: 65.7% (not reported)																		Unpublished reports	www.reuters.com/article/us-health-coronavirus-vaccine-pakistan/cansinobios-covid-19-vaccine-65-7-effective-in-global-trials-pakistan-official-says-idUSKBN2A81N0